Bioactivity:

Fenebrutinib is orally available inhibitor of Bruton's tyrosine kinase (BTK) with antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This

CAS nr:

2128304-54-9

Purity:

98%

Molecular Weight:

701,27

SMILES:

O=C1C(N2CCN1C3=NC=CC(C(C=C4NC5=NC=C(N6[C@@H](C)CN(C7COC7)CC6)C=C5)=CN(C)C4=O)=C3CO)=CC8=C2CC(C)(C)C8.[H]Cl

Formula:

C37H45ClN8O4

Pathway:

Target: